Cota, a New York City-based healthcare informatics and precision analytics company, secured $18m in funding.
Backers included Boston Millennia Partners, Novartis, Celgene, Foundation Medicine and Horizon Healthcare. In conjunction with the funding, A. Dana Callow Jr, a partner at Boston Millennia Partners, joined Cota’s board of directors.
Led by CEO Eric Schultz, and Dr. Andrew Pecora, Founder & Executive Chairman, Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols.
The patented Cota Nodal Address System (CNA) precisely categorizes patient factors, their diseases and intended therapies to measure treatment outcomes, identify variances in care and enable quality benchmarking, research, discovery and the transition to value-based medicine.
The company, which has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine, serves pharmaceutical companies, healthcare providers and insurance companies as customers.